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The introduction of thrombolysis in 2004 and thrombectomy in 2015 
were important breakthroughs in the history of acute stroke treatment 
in Denmark. There are ongoing efforts to improve acute stroke 
treatment further, and numerous clinical trials have been performed in 
order to identify a neuroprotective agent although to date none have 
been successful. The concept of using theophylline as a neuroprotective 
agent in patients with stroke began in the 1940´s; theophylline was used 
for this purpose widely in the 1960´s-1970´s, but its use was stopped in 
the early 1980´s due to a lack of evidence about its clinical 
effectiveness. 
The rationale for this thesis was based on the idea of combining new 
effective treatments and new imaging techniques with a historical 
putative neuroprotective agent (theophylline) to attempt to improve 
acute stroke treatment. This led to the Theophylline in Acute Ischemic 
Stroke (TEA-Stroke) trial conducted at Aalborg University Hospital in 
cooperation with: Aarhus University Hospital; the Centre of 
Functionally Integrative Neuroscience, Aarhus University; University 
Medical Center Hamburg-Eppendorf, Germany; Stanford University, 
Palo Alto, CA, USA; and the University of Calgary, Canada. 
The work was carried out during my employment at the Department of 
Neurology, Aalborg University Hospital in the period 2014-2020.
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Thesis at Glance 
 
Paper I 
Aim: A clinical trial protocol that evaluates the neuroprotective effect 
of theophylline in patients with acute ischemic stroke. 
Hypothesis: Previous clinical trials, which evaluate the neuroprotective 
effect of theophylline in stroke, had important limitations. 
Methods: Literature research 
Results: A phase II, proof-of-concept, randomized, placebo-controlled 
clinical trial protocol  
Conclusions: The literature is limited, dated, and previous clinical 
trials have important limitations. A new protocol was designed to offset 
these shortcomings.  
Paper II 
Aim: A randomized controlled trial to evaluate the safety and efficiency 
of theophylline, as an add-on to thrombolytic therapy, in patients with 
acute ischemic stroke. 
Primary outcome: No clinically significant safety concerns were 
identified. Neither co-primary end points, early clinical improvement, 
and infarct volume growth at the 24-hour follow-up were significantly 
different after post hoc correction for multiplicity. 
Conclusion: The trial was terminated early due to slow recruitment, 
and the small study size precludes a conclusion as to whether 
theophylline has a neuroprotective effect. However, early clinical 
improvement as a single endpoint would have been significantly better 
in patients treated with theophylline. 




Aim: A sub-study to evaluate the neuroprotective effect of theophylline 
on the imaging endpoint final infarct volume 
Design: A machine-learning model using voxel-by-voxel information 
from multi-parametric magnetic resonance imaging data and clinical 
parameters was used to predict the infarct volume for each individual 
patient virtually treated with theophylline and placebo. 
Results: The predicted follow-up lesion volumes of brain tissue 
infarction for each patient were not significantly different for virtually 
treatment with theophylline or placebo. 
Conclusion: The neuroprotective effect of theophylline, namely, 
reduced brain infarction, as shown in preclinical stroke models, was not 
present in acute ischemic stroke patients. 
Paper IV 
Aim: A sub-study to evaluate the effect of theophylline on cerebral 
perfusion in the infarct core and penumbra 
Design: Perfusion-weighted magnetic resonance imaging data at 
baseline and 3-hour follow-up were used to assess the cerebral blood 
flow, cerebral blood volume, and mean transit time in the infarct core, 
penumbra, and unaffected brain tissue. 
Results: Theophylline in acute ischemic stroke did not change the 
perfusion in the salvageable penumbra, but only affected the cerebral 
blood volume in the infarct core. 
Conclusion: In contrast to the penumbra, the infarct core is very 
unlikely to be salvageable, which might explain why theophylline failed 
to reduce the final infarct volume and failed to substantially improve 
the clinical outcome.  




CBF   cerebral blood flow 
CT  computed tomography 
DWI   diffusion-weighted imaging 
FLAIR   fluid-attenuated inversion recovery 
mcg  microgram 
mg  milligram 
ml  milliliter 
MRI   magnetic resonance imaging 
mRS   modified Rankin Scale 
NIHSS  National Institutes of Health Stroke Scale 
PWI   perfusion-weighted imaging 
TEA-Stroke   Theophylline in Acute Ischemic Stroke 
TIMI score  Thrombolysis in Myocardial Infarction 
score 





As the second commonest cause of death and the third commonest 
cause of disability worldwide, stroke is a major public health burden. 
Of the different types of stroke, most stroke patients are diagnosed with 
acute ischemic stroke, in which early reperfusion of the salvageable 
penumbra is crucial for good clinical outcomes. Theophylline is a 
vasoactive agent that might facilitate neuroprotection of the penumbra, 
based on evidence showing that it is associated with the redistribution 
of cerebral perfusion and increased cerebral blood flow in the area of a 
stroke. Data from the use of theophylline in preclinical stroke models 
have shown that it can reduce brain infarction volume, brain tissue 
edema, and mortality, and clinical case series have reported temporary 
clinical improvements in selected patients with stroke that received 
theophylline. Although these promising results were not replicated in 
two previous randomized clinical trials, these trials had important 
limitations regarding patient selection, delayed intervention, and the 
lack of use of additional revascularization therapies. 
The aim of this dissertation was to address the shortcomings of previous 
clinical trials and to evaluate the neuroprotective effect of theophylline 
in patients with acute ischemic stroke. The Theophylline in Acute 
Ischemic Stroke (TEA-Stroke) trial was a proof-of-concept trial 
designed to incorporate two sub-studies: one used a machine learning 
approach to assess the neuroprotective effect of theophylline on infarct 
volume growth, and the other involved a voxel-by-voxel-based 
evaluation of the effect of theophylline on cerebral perfusion in the 
penumbra and the infarct core.  
The main finding of this dissertation was that the co-primary endpoints 
of early clinical improvement and infarct volume growth were not 
significantly different in the theophylline group compared to the control 
group. The clinical endpoint alone indicated a potential benefit but after 
correction for multiplicity the difference was not statistically 
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significant. No significant safety concerns were identified. The 
prediction of follow-up lesions for each patient virtually treated with 
theophylline and placebo confirmed that theophylline did not reduce the 
growth in infarct volume. Finally, the cerebral perfusion analysis 
showed that theophylline did not change the perfusion in the 
salvageable penumbra, but only affected the cerebral blood volume in 
the infarct core. In contrast to the penumbra, the infarct core is highly 
unlikely to be salvageable. This might explain why theophylline failed 
to reduce the final infarct volume and failed to substantially improve 
clinical outcomes. In conclusion, the data of this thesis are not strong 
enough to support further research on the use of theophylline as a 
neuroprotective agent, because the balance between clinically 
meaningful benefits and potential harm associated with the use of 
theophylline in acute ischemic stroke remains questionable.




Stroke er en hyppig og alvorlig sygdom, som globalt er den næst 
hyppigste årsag til død og tredje hyppigste årsag til handicap. Langt de 
fleste strokes er iskæmiskbetingede og en omgående reperfusion af det 
truede hjernevæv, penumbraen, er afgørende for et godt resultat. 
Theophylline er et vasoaktivt præparat, som formodes at være 
neuroprotektiv ved at omfordele den cerebrale perfusion til gavn for det 
iskæmiske område. Theophylline har vist reduceret hjerneødem, 
hjerneskade og mortalitet i prækliniske stroke-modeller. Derudover 
beskriver case-rapports forbigående klinisk forbedring hos nogle 
stroke-patienter. Disse lovende resultater kun ikke reproduceres i 
kliniske forsøg, som dog har haft betydelige svagheder: 
Patientselektion, forsinket intervention og manglende 
revaskulariserende behandling.  
Formålet med afhandlingen var at belyse den neuroprotektive effekt af 
theophylline hos patienter med akut cerebral iskæmi. I designet af 
protokollen ”Theophylline in acute ischemic stroke” (TEA-Stroke) blev 
der taget hensyn til de udfordringer fra de tidligere studier og 
inkluderede to substudier: Et studie anvendte kunstig intelligens til at 
detektere en eventuel subtil neuroprotektiv effekt af theophylline og det 
andet studie vurderede effekten af theophylline på den cerebrale 
perfusion i penumbraen og i infarktkernen. 
Hovedresultatet af afhandlingen, er at de to primære endepunkter tidlig 
klinisk forbedring og infarktvækst ikke viste signifikant forskel mellem 
theophylline- og kontrolgruppen. Tidlig klinisk forbedring alene ville 
have været til fordel for theophylline, men betragtes ikke statistisk 
signifikant efter korrektur for flere målinger ved to primære 
endepunkter. Studiet viste ingen kliniske relevante bivirkninger. 
Substudierne bekræftede at theophylline ikke reducerede 
infarktvæksten og viste at theophylline ikke ændrede perfusionen i 
penumbraen. Theophylline påvirkede udelukkende den cerebrale 
blodvolumen i infarktkernen. I modsætning til den potentielle 
reversible skade i penumbraen er skaden i infarktkernen som regel 
irreversibel og det kan forklare hvorfor theophylline ikke reducerede 
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den endelige infarktvolumen og ikke substantielt forbedrede det 
kliniske resultat. 
Der konkluderes, at resultaterne fra denne afhandling ikke underbygger 
ny forskning som undersøger den neuroprotektive effekt af 
theophylline, idet det fremstår tvivlsomt, hvorvidt den viste kliniske 
effekt står mål med de potentielle bivirkninger.




The main purpose of this dissertation was to evaluate the 
neuroprotective effect of theophylline in patients with acute ischemic 
stroke. 
Stroke 
As the second commonest cause of death and the third commonest 
cause of disability worldwide, stroke is a major public health 
problem.(1) In Denmark, there were approximately 12.000 new stroke 
cases in 2019, with an associated mortality rate of 8% within the first 
month.(2) In the majority of stroke patients (85%), the etiology of the 
stroke is acute ischemia, which is characterized by an insufficient blood 
supply to the brain secondary to cerebral vessel occlusion. Persistent 
vessel occlusion leads to enlargement of the ischemic area(3) and 
worsening of the clinical outcome.(4) For every minute that a typical 
acute ischemic stroke patient with occlusion of the middle cerebral 
artery is left untreated, it is estimated that approximately 1.9 million 
neurons are lost.(5) Accordingly, early reperfusion of the ischemic area 
is crucial for a good clinical outcome. 
The treatment of acute ischemic stroke has advanced markedly over the 
last few years. Acute revascularization with intravenous recombinant 
tissue plasminogen activator within a time window of 4.5 hours after 
symptom onset is the current treatment standard in Denmark.(4,6,7) 
Thrombolysis has also been shown to be effective in patients with an 
unknown time of stroke onset, if the patients are selected using specific 
brain imaging criteria.(8) However, recent studies have shown 
conflicting results for the use of thrombolysis in an extended time 
window up to 9 hours from the onset of stroke.(9,10) 
Endovascular thrombectomy, which involves mechanical removal of 
the blood clot within the first 6 hours after the onset of stroke, is an 
established therapy in cases of large vessel occlusion(11,12) and 
became a standard treatment in Denmark in 2015. Recent clinical trials 
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of endovascular thrombectomy in the extended time window of up to 
24 hours from the onset of stroke have shown excellent clinical 
outcomes, with a very low number-needed-to-treat in terms of 
achieving daily functional independence.(13,14) 
The selection of patients with acute ischemic stroke eligible for 
revascularization therapies depends not only on the time of symptom 
onset but also on acute brain imaging. 
Brain imaging in acute ischemic stroke 
Brain imaging using computed tomography (CT) or magnetic 
resonance imaging (MRI), in combination with CT angiography or 
magnetic resonance angiography, is essential to exclude stroke mimics 
and hemorrhage, to define the extent of the acute ischemia, and to 
determine the cause and mechanism of the stroke particularly in relation 
to the identification of large vessel occlusion.(15) Perfusion-weighted 
positron emission tomography imaging facilitates differentiation 
between the core of acute ischemia that turns into infarction despite 
recanalization, the oligemic area that rarely turns into infarcted tissue, 
and the hypoperfused area of brain tissue with preserved but at-risk 
neuronal integrity known as the ischemic penumbra.(16) The existence 
of an ischemic penumbra in stroke, comprising an area of brain tissue 
surrounding the infarct core with slower cell death, was supported by a 
baboon stroke model described by Astrup et al. in 1977.(17) The brain 
cells in the ischemic penumbra were found to be functionally inactive 
(electrically silent), but with preserved structure and the ability to 
survive for a period of time.  
Diffusion-weighted MRI (DWI) is an established technique routinely 
used in the clinical setting to delineate the core of acute ischemia in 
patients with ischemic stroke (18) and perfusion-weighted MRI (PWI) 
is used to detect the area of cerebral hypoperfusion(19). The DWI/PWI-
mismatch is believed to represent the penumbra.(20) The infarct 
volume and the proportion of ischemic penumbra salvaged correlate 
well with clinical outcomes in stroke patients.(21) Patients with 
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DWI/PWI-mismatch respond better to early recanalization than patients 
without mismatch.(22) Even though the presence of an ischemic 
penumbra appears to be a favorable selection criteria, and some phase 
II clinical trials have shown that the mismatch concept is suitable for 
selecting patients most likely to benefit from acute treatment(23,24), 
the overall results of subsequent clinical trials have been 
conflicting.(25–29) As a result, multimodal imaging, including imaging 
of the ischemic penumbra outside of clinical trials, is currently not 
recommended in order to prevent delayed revascularization within the 
conventional time windows. However, the penumbra selection criteria 
are recommended in the extended time window to select patients for 
endovascular therapy(30) if the remaining eligibility criteria of the 
corresponding clinical trials are fulfilled.(13,14) 
Delayed revascularization in acute ischemic stroke, whether achieved 
through thrombolytic therapy or endovascular thrombectomy, is 
associated with poor clinical outcomes.(6,31) In a meta-analysis of 
pooled individual patient data from randomized clinical trials, the time 
from symptom onset to randomization was 121–240 minutes in the 
majority of patients.(31) In another meta-analysis of clinical trials 
evaluating the use of thrombolytic therapy, the median onset to 
treatment time was 144 minutes.(32) To contrast, in another meta-
analysis, the onset to treatment time was >180 minutes in more than 
two-thirds of all included patients.(4) Thrombolysis data from the 
Danish Stroke Registry in 2019 showed a median time of 100 minutes 
from onset to admission and a median time of 28 minutes from 
admission to thrombolysis (resulting in an overall median onset to 
treatment time of 128 minutes).(33)  
Neuroprotective therapy in acute ischemic stroke 
Even though the time periods of pre- and inter-hospital management of 
acute stroke patients have shortened substantially over the past 20 years, 
the current data still show a notable delay from onset to treatment. For 
this reason, a neuroprotective treatment that can salvage the ischemic 
penumbra and thus preserve neuronal integrity and prevent subsequent 
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brain damage is desirable. Without sufficient revascularization and 
reperfusion of the penumbra, the brain cells in the penumbra will die 
and the infarct core will expend.(34) 
The exact molecular mechanisms behind cell death in stroke are still a 
matter of debate, but it is widely accepted that excitotoxicity, oxidative 
stress, free radicals, and apoptosis are involved.(35–37) A large number 
of different neuroprotective strategies have been assessed in animal 
models of stroke. To date, these promising preclinical data have not 
been translated into clinical trials demonstrating improved clinical 
outcomes in patients with acute ischemic stroke.(38) 
Currently, the only recommended therapy for acute ischemic stroke is 
revascularization with thrombolysis and/or endovascular 
thrombectomy.(30) Thrombolysis with tissue plasmin activator has 
been shown to be associated with clinical benefit but has also shown 
neurotoxic effects in animal models of stroke.(39,40) However, the 
results from preclinical data have led to the conclusion that a 
combination of drugs might improve neuroprotection in a way that is 
not possible with monotherapy.(41) The integration of neurovascular 
revascularization therapy and neuroprotective cellular therapy may 
result in further improvements in the safety of thrombolysis and, 
crucially, might extend the therapeutic time window.(42) The recent 
ESCAPE-NA1 randomized controlled clinical trial was able to combine 
vascular and cellular neuroprotective approaches while assessing use of 
the neuroprotective agent nerinetide in acute ischemic stroke patients 
treated with thrombolysis and/or endovascular thrombectomy.(43) The 
trial results were neutral in relation to the primary endpoint, which was 
defined as a good clinical outcome. Even though the trial was well-
designed, the promising neuroprotective effect demonstrated in a 
preclinical stroke model was not translated into clinical efficacy in 
humans.(44) However, the authors reported a treatment effect among 
patients not treated with thrombolysis, probably related to a 
pharmacological interaction between nerinetide and the thrombolytic 
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agent alteplase, and they suggested that a neuroprotective effect in 
human stroke might still be possible.(43) 
Theophylline 
Methylxanthines are alkaloids found naturally in chocolate, coffee, and 
tea. The most abundant methylxanthines in chocolate, coffee, and tea 
are theobromine, caffeine, and theophylline, respectively.(45). 
Theophylline is thought to act as a nonselective phosphodiesterase 
inhibitor, as an adenosine receptor antagonist with an effect on smooth 
muscles, and as an anti-inflammatory agent (because of its roles as an 
inhibitor of nuclear factor-κB, inhibitor of phosphoinositide 3 kinase-δ, 
activator of interleukin-10 secretion, activator of apoptosis of 
inflammatory cells, inhibitor of cell death via inhibition of poly[ADP-
ribose]polymerase-1, and activator of histone deacetylase activity).(46) 
Theophylline is a pharmacologically active substance that is combined 
with ethylenediamine for better solubility. Previous publications have 
referred to theophylline as well as the combination of theophylline and 
ethylenediamine, otherwise known as aminophylline. Henceforth, 
theophyllamine and aminophylline will be referred to as theophylline. 
Theophylline has a number of well-known clinical actions (Figure 1). 
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In Denmark, theophylline is licensed for the treatment of asthma and 
bronchial spasm. Off-label applications rely on the central nervous 
system stimulatory effect in the treatment of apnea in preterm 
infants(47) and the diuretic effect to prevent contrast-induced renal 
failure(48). 
Theophylline and stroke 
Previous studies have demonstrated an inverse relationship between tea 
consumption and the risk of stroke and cerebrovascular disease in 
general.(49–51) However, the neuroprotective effect of theophylline in 
acute ischemic stroke is controversial.  
The first response of brain tissue to ischemia is vasodilatation in the 
involved vascular territory in an attempt to increase the regional 
cerebral blood volume and maintain cerebral blood flow.(52) Naturally, 
adenosine acts as an endogenous mediator between cerebral 
metabolism and blood flow via pial vasodilatation(53,54). 
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Phosphodiesterase inhibition increases the intracellular concentration 
of cyclic adenosine monophosphate causing vasodilatation through the 
activation of calcium-activated potassium channels and adenosine 
triphosphate-sensitive potassium channels.(55) Theophylline acts as a 
phosphodiesterase inhibitor causing vasodilatation; however, it also 
acts as a competitive adenosine receptor antagonist(56) thereby, also 
causing cerebral vasoconstriction.(57,58) This controversy is the reason 
that the vasoactive effects of theophylline on ischemic brain tissue are 
still unexplained. Furthermore, the cerebral vasoconstrictive effect of 
theophylline, associated with reduced global and regional cerebral 
blood flow, has been shown in previous studies.(59–61) Skinhøj and 
Paulson evaluated stroke patients using the Xenon-133 arterial injection 
technique and showed decreased regional cerebral blood flow in areas 
of normal brain tissue and, in some patients, increased regional cerebral 
blood flow in the areas of brain tissue affected by stroke.(59) The 
authors concluded that this “inverse intracerebral steal phenomenon” 
might explain the favorable clinical effect of theophylline. For instance, 
the authors observed a remarkable and reproducible clinical 
improvement, with diminished right hemiparesis and aphasia, in one 
patient with an occluded internal carotid artery and increased cerebral 
blood flow in the territory of the left middle cerebral artery following 
the administration of theophylline. The opposite of this, a “reverse 
intracerebral steal phenomenon”, has been described in patients with 
MRI-verified acute ischemic stroke, in association with the presence of 
a perfusion/diffusion-mismatch and fluctuating clinical symptoms 
suspicious for a salvageable penumbra; these patients showed 
vasodilatation of the intracerebral vessels in areas of normal brain 
tissue, leading to reduced cerebral blood flow in the area of infarction 
when exposed to hypercapnia from hypoventilation or treatment with 
acetazolamide.(62) 
Animal stroke models with pre- or per-conditioning using theophylline 
have shown reduced ischemic brain damage, perifocal edema, and 
mortality.(63–65) The effect of theophylline in stroke in humans has 
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been described in several case series and two randomized clinical trials; 
the case series described a considerable and immediate clinical 
improvement, albeit only temporarily and not in all patients.(66–72)  
Two randomized double-blind, placebo-controlled studies have been 
performed with theophylline in stroke patients.(73,74) The study by 
Geismar et al. included 79 patients who received a bolus of theophylline 
or placebo and showed a significant increase in the frequency of early 
improvement in the group treated with theophylline (38% versus 15%). 
However, there was no significant difference at the 3-week follow-up 
point(73). Britton et al. randomized 46 patients to receive either a bolus 
followed by continuous infusion of theophylline or placebo over 3 
days.(74) The authors described a trend toward better functional 
outcome in the theophylline group at 3 weeks, but without a significant 
difference when deterioration and mortality were accounted for. Both 
of these studies had important limitations, as follows:  
1. The diagnosis of stroke was made without brain imaging and was 
based on clinical evaluation. 
2. The mortality of 22–23% within 3 weeks was high in both studies 
and indicated a selection bias towards patients with severe stroke and 
predominantly irreversible brain damage.  
3. The time of the study intervention was, on average, delayed by 20 
hours (one-third of patients were treated beyond 24 hours; Geismar et 
al.) and 40 hours (range 18–114 hours; Britton et al.) following the 
onset of stroke. Thus, most patients in these two trials were treated at a 
time point where established irreversible brain infarction was presumed 
to have occurred and, presumably, there was little, or no salvageable 
penumbra left. 
4. Theophylline has no known thrombolytic effect. Clinical 
improvement and reduction in infarct volume growth due to improved 
perfusion of the penumbra will presumably be only temporary, as no 
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thrombolytic agent or revascularization therapy was available at the 
time the studies were performed.   
Despite the substantial limitations of these studies, which can be 
summarized as inappropriate patient selection, delayed intervention, 
and a lack of revascularization therapy, no further clinical trials of 
theophylline in acute ischemic stroke have been performed. 
Consequently, a Cochrane review, primarily based on the limited data 
from the aforementioned clinical trials, concluded that there is not 
enough evidence to assess whether theophylline or its analogs are safe 
and improve outcomes in patients with acute ischemic stroke.(75) 
Based on these data, it remains unknown whether theophylline has a 
neuroprotective effect in acute ischemic stroke. Reperfusion of the 
salvageable penumbra despite occlusion of the culprit vessel may 
explain the neuroprotective effect of theophylline as an adjunct to 
thrombolytic therapy. This may offer the potential to reduce the final 
infarct volume with improved clinical outcome but may also offer an 
extended time window for revascularization therapy. No previous study 
has evaluated theophylline as an add-on to thrombolytic therapy and 
there are no ongoing trials on this topic registered with the U.S. 
National Institutes of Health (www.ClinicalTrials.gov) or EudraCT 
(www.clinicaltrialsregister.eu).






The overall aim of this PhD thesis was to evaluate the potential 
neuroprotective effect of theophylline in patients with acute ischemic 
stroke. This was achieved through four studies, as follows: 
 
Study I 
A clinical trial protocol that evaluated the neuroprotective effect of 
theophylline in patients with acute ischemic stroke.  
 
Study II 
A randomized controlled trial to evaluate the safety and efficiency of 




A sub-study to evaluate the neuroprotective effect of theophylline on 
the imaging endpoint of final infarct volume. 
 
Study IV 
A sub-study to evaluate the effect of theophylline on cerebral perfusion 
in the infarct core and penumbra. 
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Material and Methods 
This PhD dissertation is based on the ThEophylline in Acute Ischemic 
Stroke (TEA-Stroke) trial, an investigator-initiated two-center, proof-
of-concept, phase II clinical trial with a randomized, double-blind, 
placebo-controlled design. 
Ethical considerations and dose justification 
This study was performed in accordance with the Declaration of 
Helsinki and was approved by the Danish Health and Medicines 
Authorities (ref no 2013050908) and the local institutional ethics 
review board (ref no N-20130034). Written informed consent was 
obtained from all subjects before participation 
Theophylline is not currently licensed for the treatment of acute 
ischemic stroke. In previous randomized stroke trials, theophylline was 
administrated as a repetitive bolus or as a bolus followed by continuous 
infusion. In these trials, none or only mild adverse events such as nausea 
were registered.(73,74) There is no documented evidence in the 
literature that theophylline causes bleeding complications, including 
intracerebral hemorrhage. 
The usual loading dose of theophylline is 5 mg/kg body weight in 
patients with acute bronchial spasm that have not been preloaded with 
theophylline. It is recommended that the calculation of theophylline 
dosage is based on ideal body weight, as theophylline distributes poorly 
within body fat. On average, a dose of 4.6 mg/kg theophylline 
administrated over 30 minutes will produce a maximum post-
distribution serum concentration of 10 mcg/ml, with a range of 6–16 
mcg/ml (Food and Drug Administration-approved theophylline 
information for healthcare professionals [www.drugs.com]). Clinically 
important pulmonary improvement usually requires serum theophylline 
concentrations to be greater than 10 mcg/ml. Adverse reactions with 
peak serum theophylline concentrations less than 20 mcg/ml are 
generally mild and mainly transient caffeine-like adverse reactions. The 
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frequency and severity of adverse reactions are increased with peak 
serum theophylline concentrations greater than 20 mcg/ml. More severe 
adverse reactions are seen in acute or chronic overdose associated with 
theophylline concentrations greater than 30 mcg/ml. 
A dose-escalation study of theophylline in acute ischemic stroke does 
not exist. The bolus dose used in most of the case series and in both 
randomized clinical trials in acute ischemic stroke was less than the 
bolus dose usually used in patients with acute bronchial spasm. An 
intravenous bolus of 200 mg and 230 mg theophylline without 
adjustment for body weight was used by Britton et al.(74) and Geismar 
et al.(73), respectively. Assuming an average body weight of 70 kg, this 
corresponds to a theophylline concentration of 2.9 mg/kg and 3.3 
mg/kg, respectively. On average, these dosages would be too small to 
reach theophylline concentrations greater than 10 mcg/ml, which makes 
the risk of typical adverse reactions less likely. Nevertheless, a relevant 
effect in the TEA-Stroke trial could be expected, as almost the same 
dosage (an intravenous bolus of 250 mg theophylline) has been shown 
to result in cerebral vasoconstriction when measured 5 minutes, 25 
minutes, and 45 minutes after administration.(76) The same authors 
confirmed the elimination of theophylline from serum by first order 
rates with half-lives of 5.4–9.0 hours. This is consistent with the 
temporary clinical improvement observed up to six hours after the 
administration of 220 mg theophylline.(59) 
Studies I and II 
The trial protocol considered the important limitations of the previous 
clinical trials and provided, for the first time, a trial design incorporating 
theophylline and revascularization therapy together. Eligibility for 
thrombolytic therapy within 4.5 hours of symptom onset and MRI-
verified acute ischemic stroke with perfusion/diffusion mismatch 
suspicious for salvageable penumbra were chosen as the main inclusion 
criteria. The trial was designed as a double-blind, placebo-controlled, 
two-center trial. A clinical assessment of stroke severity using the 
National Institute of Health Stroke Scale (NIHSS) was performed at 
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baseline, and at 3- (range 2–3) and 24- (range 22–32) hour follow-
up.(77,78) The NIHSS measures the severity of a stroke (NIHSS scores 
0–4 correspond to mild stroke symptoms, NIHSS scores 5–15 to 
moderate, NIHSS scores 16–20 to moderate-to-severe, and NIHSS 
scores ≥ 20 to severe stroke; Appendix 1). The modified Rankin Scale 
(mRS) was applied to assess the functional outcome of patients at the 
3-month follow-up point (0 = no symptoms, 1 = no significant 
disability, 2 = slight disability, 3 = moderate disability, 4 = moderate 
severe disability, 5 = severe disability, and 6 = dead; Appendix 
2).(77,79–81) Imaging assessment with multiparametric MRI was 
performed at baseline, 3-hour follow-up, and 24-hour follow-up. An 
overview of the patient flow is published in the European Stroke Journal 
(82) and the detailed schedule of assessments is shown in figure 2. The 
24-hour follow-up was the timepoint for the primary endpoint 
assessment and the 3-hour follow-up was added for the sub-study 
assessing the effect of theophylline on the infarct core and penumbra. 
Figure 2: Patient flow and assessment 
 
ECG: electrocardiography; MRI: magnetic resonance imaging; mRs: 
modified Rankin Scale; NIHSS: National Institute of Health Stroke 
Scale; rtPA: recombinant tissue plasmin activator 





The following co-primary end points at the 24-hour follow-up point 
were chosen: 
• Clinical improvement, defined as the absolute change in the NIHSS 
score from baseline to follow-up; and 
• The proportion of the penumbra salvaged, defined as the proportion 
of the diffusion/perfusion mismatch on the baseline imaging that 
did not progress to final infarction on the imaging performed during 
follow-up. 
Early clinical improvement and penumbra salvage were the surrogate 
markers chosen as co-primary end points as they were associated with 
good long-term clinical outcomes (25,83–85) and have been 
successfully applied in a well-designed clinical trial with a small sample 
volume.(70) The effect size of theophylline as an add-on to 
thrombolytic therapy is unknown. A sample size of 60 patients in each 
treatment group was chosen in the TEA-Stroke trial protocol (Study I). 
This calculation was based on the sample size estimates for proof-of-
principle phase II MRI studies in stroke by Donnan et al.(86) However, 
the interpretation of this reference was incorrect and was thus replaced 
by a post hoc sample size calculation (Study II). Furthermore, a post 
hoc Bonferroni correction was performed in order to consider the co-
primary end points using multiple comparisons. 
The TEA-Stroke trial was performed at the stroke units of Aalborg 
University Hospital and Aarhus University Hospital. The trial protocol 
included 120 patients with acute ischemic stroke and a significant 
penumbral mismatch as determined by MRI. Patients were randomized 
1:1 to receive either 200 mg theophylline or placebo as an add-on to 
standard thrombolytic therapy. Three protocol amendments were made 
due to the unexpected low recruitment rate (Figure 3). 
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Figure 3: Recruitment rate 
 
Red = expected recruitment, blue = monthly recruitment, black = total 
recruitment.  
 
Protocol amendment PA01 (January 28th, 2015) 
Most patients who were otherwise eligible for thrombolytic therapy did 
have a less severe stroke defined by an NIHSS score <6. In cases of 
severe stroke, patients were often unable to provide informed consent. 
The inclusion criterion NIHSS score was changed from ≥ 6 to ≥ 4 in 
order to improve the recruitment rate.  
 
Protocol amendment PA02 (February 24th, 2016) 
In the TEA-Stroke protocol, a semi-automatic in-house software was 
chosen to assess the MRI perfusion/diffusion mismatch. Unfortunately, 
several potential trial candidates were excluded, as the semi-automatic 
calculation was not possible in time due to technical reasons. To 
improve the recruitment rate, the visual assessment of the 
perfusion/diffusion mismatch based on the MRI-scanner software was 
allowed if the semi-automatic calculation was not available in a timely 
manner. 




Protocol amendment PA03 (June 20th, 2016) 
The study period was extended to February 1st, 2019 to compensate for 
the delayed start of recruitment and the unexpected low recruitment 
rate. Furthermore, the technically challenging and time-consuming 
perfusion/diffusion-mismatch inclusion criterion was omitted by 
simplifying the scanning protocol to further improve the recruitment 
rate. For that same reason, visit 2 at 2–3 hours was omitted to improve 
the feasibility of the study. An interim analysis was scheduled after the 
inclusion of 60 patients. 
 
The protocol amendments necessitated a change in the co-primary end 
points, as omitting the perfusion-weighted imaging meant that it was no 
longer possible to assess the proportion of penumbral salvage as an end 
point. The study outcomes were finally adapted as follows: 
 
Co-primary end points 
• The clinical improvement, defined as the absolute change in the 
NIHSS score between baseline and follow-up. 
• The proportion of infarct volume growth, defined as the proportion 
of co-registered DWI lesions at the 24-hour follow-up that were not 
present at baseline ([DWIfollow-up - DWIbaseline]/DWIbaseline × 100%). 
 
Safety end points 
• Parenchymal hemorrhage(s) at the 24-hour follow-up point 
• Symptomatic intracerebral hemorrhage(s) at the 24-hour follow-up 
point 
• Death within 90 days 
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Secondary clinical endpoints 
• Major clinical improvement (≥50% improvement in NIHSS score 
between baseline and 24-hour follow-up) 
• Favorable functional outcome at 90 days (mRS score 0 or 1) 
• Improved categorical functional outcome at 90 days 
 
Secondary imaging endpoints 
• Recanalization rate 
• Penumbral salvage 
 
The steering committee decided to stop the trial after 3.5 years of 




This pre-planned TEA-Stroke subgroup analysis was designed to detect 
a subtle neuroprotective effect of theophylline on infarct volume 
growth. The main selection criteria for this subgroup analysis were a 
multiparametric MRI including diffusion-and perfusion MRI at 
baseline, and a follow-up MRI at 24 hours. The AnToNIa software 
tool(87) was used to extract voxel-by-voxel information on: the tissue 
type probability, anatomical location, distance to the infarct core, 
apparent diffusion coefficient (ADC) value, cerebral blood flow (CBF) 
value, cerebral blood volume (CBV) value, mean transit time (MTT) 
value, and time-to-maximum (Tmax) value.(87) These imaging 
features were combined with the following clinical parameters: age, 
sex, baseline NIHSS score, and time from stroke onset to time of study 
administration. A predictive modeling approach was chosen to compare 
the follow-up lesions of patients virtually treated with theophylline and 
placebo. Previous studies using this approach showed a better 
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performance in tissue outcome prediction compared to simple perfusion 
parameter thresholding(88–91), and this approach has been used 
successfully for intra-individual comparisons of virtual treatments.(92) 
Two random forest machine learning models were trained, one with the 
training sets from patients with theophylline and another with the 
training sets from patients treated with placebo. Finally, the lesion 
outcome for both treatment options in each patient was predicted, while 
the patient used for lesion outcome prediction was excluded from the 
training set in order to prevent double-dipping (the leave-one-out 
approach is illustrated in Figure 4). This approach allowed the 
assessment of the final imaging outcome based on 8 imaging and 4 
clinical parameters, and essentially doubled the sample size by 
simulating both treatment outcomes for each patient. 
 
Figure 4: Leave-one-out approach 
 
The predicted infarct volume for T1, virtually treated with theophylline, 
was based the imaging data in the theophylline group without the T1 
dataset (leave-one-out), and the predicted infarct volume when virtually 
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treated with placebo was based on all imaging data from the placebo 
group. The same was applied for T2, T3, …T34, and vice versa for each 
patient in the placebo group. 
   
Study IV 
This pre-planned TEA-Stroke subgroup analysis was designed to 
evaluate the effect of theophylline on cerebral perfusion. The main 
selection criteria for this subgroup analysis were multiparametric MRI 
scans including diffusion and perfusion-weighted imaging at baseline 
and 3-hour follow-up. Theophylline has a half-life of 3–9 hours, and it 
was expected that the effect of theophylline on cerebral perfusion was 
still present at the 3-hour follow-up point. The AnToNIa software tool 
was used to calculate the CBF, CBV, MTT, and Tmax of the residual 
function. Relative perfusion maps (rCBF, rCBV, rMTT, and rTmax) 
were computed using the mean values form the contralateral 
hemisphere. The mean values for each parameter were calculated from 
the infarct core region of interest (ROI), the penumbra ROI (defined by 
perfusion-diffusion mismatch), and the unaffected tissue ROI (infarct 
core and penumbra ROI subtracted from the affected hemisphere; 
Figure 5). The same baseline ROI for infarct core, penumbra, and 
unaffected tissue was used to calculate the mean rCBF, rCBV, and 
rMTT at the 3-hour follow-up point. To evaluate the dynamics in the 
penumbra over time, two different penumbra ROIs at the 3-hour follow-
up point were applied: the ROI mask reflecting the penumbra at 
baseline (penumbraROI-0h) and the ROI mask reflecting the actual 
penumbra at 3 hours (penumbraROI-3h). Finally, the absolute values and 
the change from baseline to 3-hour follow-up were compared between 
the theophylline group and the control group. Regarding the clinical 
assessment, the NIHSS score at baseline and the 3-hour follow-up point 
was assessed to determine for the presence of early clinical 
improvement, and vital signs were measured to assess the positive 
inotropic and chronotropic effects of theophylline. 
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Figure 5: Semi-automatic imaging post-processing using the AnToNIa 
software tool 
 
A = T-max map with a hypoperfused cortical area in the left middle 
cerebral artery territory; B = apparent diffusion coefficient (ADC) map 
with hypodensity in the hypoperfused area, indicating the infarct core; 
C = ADC map with cerebrospinal fluid segmentation (blue); D = 
segmentation of the infarct core region of interest (ROI; red), E = 
segmentation of the infarct core ROI (red) and penumbra ROI (bright 
green); F = segmentation of infarct core ROI (red), penumbra ROI 
(bright green), and unaffected tissue ROI (light green).





During the study period from September 2014 to December 2017, the 
recruiting sites of Aalborg University Hospital and Aarhus University 
Hospital treated 1.573 stroke patients with thrombolysis. Sixty-seven 
patients were enrolled, and 64 patients were finally randomized to the 
TEA-Stroke trial (Figure 6). The reasons for not being enrolled in the 
trial and the reasons for screening failure are shown in the Consolidated 
Standards of Reporting Trials (CONSORT) flow diagram published in 
Stroke (93). 
 
Figure 6: CONSORT flow diagram (Study II, III, IV) 
 
MRI indicates magnetic resonance imaging; PWI perfusion weighted 
imaging 
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Finally, 33 patients were randomized to the theophylline group and 31 
patients were randomized to the control group (Study II). Fifty-two 
patients fulfilled the criteria for the subgroup analysis to predict the 
lesion outcome for both treatment options in each patient (Study III), 
and 24 patients fulfilled the criteria for the subgroup analysis to evaluate 
the effect of theophylline on cerebral perfusion (Study IV). 
The baseline characteristics, imaging characteristics, and procedural 
data were similar between the theophylline group and the control group 
in Studies II, III, and IV except for diabetes mellitus, which was 
commoner in patients in the theophylline group than in the control 
group (significant difference in Study III only). 
Study II 
Theophylline was associated with an improved NIHSS score between 
baseline and the 24-hour follow-up point of 4.7 points (standard 
deviation [SD] 5.6) compared to an improvement of 1.3 points (SD 7.5) 
in the control group (p=0.044). Growth in infarct volume was on 
average 141.6% (SD 126.5) in the theophylline group and 104.1% (SD 
62.5) in the control group (p=0.146). 
No clinically significant safety concerns were identified, and the safety 
end points, secondary clinical endpoints, and secondary imaging end 
points were similar between the two groups (Table 1). 
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Table 1: Efficacy and safety outcomes (93) © 2020 AHA/ASA Journals 
 
NA indicates not applicable due to small sample size; NIHSS, National 
Institute of Health Stroke Scale; and TIMI, Thrombolysis in Myocardial 
Infarction grading of arterial obstruction (score 0, complete occlusion; 
1, severe stenosis; 2, mild to moderate stenosis; and 3, normal arterial 
caliber). 
*Adjusted for age (≤60 or >60 y) and stroke severity (NIHSS of ≤15 or 
>15) at randomization. 
†Adjusted for age (≤60 or >60 y) and stroke severity (NIHSS of ≤15 or 
>15) at randomization and prespecified potential confounding 
variables. 
‡Post hoc Bonferroni correction applied. 
§N=30 for median proportion of infarct growth in the control group as 
MRI follow-up at 24 h was not possible in 1 patient with severe 
neurological deterioration due to remote ICH. 
∥Fisher exact test due to low number of patients. 
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¶Penumbra salvage assessment was available in 22 patients in the 
theophylline group and in 21 patients in the control group. 
#Recanalization was achieved in 9 out of 14 patients in the theophylline 
group and in 10 out of 12 patients in the control group. 
© 2020 AHA/ASA Journals  
 
The improvement of categorical functional outcome on the modified 
Rankin Scale at 90 days is illustrated in Figure 7. 
 
Figure 7: Functional outcome at 90 days: (93) © 2020 AHA/ASA 
Journals 
 
Patients in the theophylline group were treated with theophylline as an 
add-on to thrombolytic therapy. Patients in the control group were 
treated with thrombolytic therapy alone. Scores on the modified Rankin 
scale range from 0 to 6 (0, no symptoms; 1, no clinically significant 
disability; 2, slight disability; 3, moderate disability; 4, moderately 
severe disability; 5, severe disability; and 6, death). There were no 
patients with modified Rankin Scale score of 5 or 6 in the theophylline 
group. The adjusted common odds ratio for favorable outcome in the 
theophylline group was 1.44 (95% CI, 0.58–3.59; P=0.432). 
© 2020 AHA/ASA Journals 




The mean ischemic lesion volume at the 24-hour follow-up point based 
on the follow-up T2-FLAIR MRI imaging was 13.9 ml (SD 20.3) for 
the theophylline group and 11.7 ml (SD 19.3) for the control group 
(p=0.92). When applying the predictive modeling approach, the mean 
predicted ischemic lesion volume was 11.4 ml (SD 18.7) for patients 
virtually treated with theophylline and 11.2 ml (SD 17.3) for patients 
virtually treated with placebo (p=0.86). 
The predicted ischemic lesion volumes were similar in patients with and 
without the presence of a penumbra (p=0.89), in patients with cortical 
versus lacunar infarctions (p=0.88), patients with and without large 
vessel occlusion (p=0.57), and in patients with and without 
revascularization at follow-up (p=0.35; Figure 8). 
Figure 8: Subgroup analysis (Study III) 
 
Box-whisker diagrams depicting the predicted volume of follow-up 
lesions plotted as the difference between the two predictions 
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(theophylline and placebo) for each patient. Values <0 indicate that 
theophylline is better than placebo, and values >0 indicate that placebo 
is better than theophylline, indicating no significant difference for 
patients with and without tissue-at-risk at baseline for patients with: 
cortical vs. lacunar infarction, with and without large vessel occlusion 
at baseline, and with and without recanalization at follow-up. 
 
Likewise, the difference between the predicted ischemic lesion volume 
for each patient virtually treated with theophylline or placebo was not 
significantly different between small and large infarct volumes (Figure 
9). 
 
Figure 9: Bland-Altman plot of the difference between the two follow-
up lesion volumes for theophylline and placebo over the average of the 
two predicted volumes for each patient (Study III) 
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Values <0 indicate that theophylline is better than placebo while values 
>0 indicate that placebo is better than theophylline. The middle line 
indicates the mean difference between the predicted values, and the 
upper and lower lines indicate the higher and lower limits of agreement 
(twice the standard deviation), respectively. 
 
Study IV 
The mean rCBF, rCBV, and rMTT values at baseline, at 3-hour follow-
up, and the change from baseline to 3-hour follow-up in relation to the 
infarct core, the penumbra, and the unaffected tissue were similar 
between the theophylline group and the control group (Figure 10). 
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Figure 10: Mean relative cerebral blood flow (rCBF), relative cerebral 
blood volume (rCBV), and relative mean transit time (rMTT); Study IV 
 
Mean values with confidence interval (red=theophylline group, 
blue=control group) 
 
The only exception was the mean rCBV in the infarct core. There was 
no significant difference between the theophylline group and the control 
group at baseline (p=0.34), but rCBV was significantly higher at the 3-
hour follow-up point (p<0.01) in the theophylline group. The mean 
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rCBV change from baseline to follow-up was significantly different 
(p=0.04) in the theophylline group. 
 
Table 2: Perfusion parameters (Study IV) 
 
 
INFARCT CORE PENUMBRA UNAFFECTED TISSUE 
 Theo-
phylline 
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Abbreviation: SD = standard deviation.  
a Two-sample Wilcoxon rank-sum test, b Two-sample t-test with equal 
variances 
Early clinical improvement with an improved NIHSS score ≥4 points 
between baseline and the 3-hour follow-up point was present in 1 (8%) 
patient in the theophylline group compared to 2 (18%) patients in the 
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control group (p=1). The rate of early recanalization was 100% (7/7) in 
the theophylline group and 50% (2/4) in the control group (p=0.109). 
The mean heart rate increased significantly by 11 beats per minute (SD 
26) in the theophylline group compared to a decrease by 9 beats per 
minute (SD 14) in the control group (p<0.05). The mean systolic and 
diastolic blood pressures were similar in both groups. 
The mean difference in rCBF, rCBV, and rMTT from baseline to the 3-
hour follow-up point in the follow-up penumbra defined by the baseline 
ROI (penumbraROI-0h) and based on the actual penumbra at follow-up 
(penumbraROI-3h) was similar in the theophylline group and the control 
group (Table 3). 
 
Table 3: Perfusion parameters within the different penumbra ROIs at 
baseline and follow-up 
 Theophylline group 
(n = 13) 
Control group 
(n = 11) 
 
PenumbraROI-0h 0 h 3 h Mean Δ 0 h 3 h Mean Δ p-value* 






(0.19) -0.08 (0.21) 0.3236 
Mean rMTT 6.02 (3.17) 2.22 (1.85) -3.80 (4.17) 5.68 (3.17) 2.34 (1.95) -3.35 (3.16) 0.7701 
Mean rCBF 0.70 (0.21) 0.82 (0.17) 0.11 (0.21) 0.63 (0.17) 0.80 (0.21) 
0.17 
(0.16) 0.5079 
PenumbraROI-3h    
Mean rCBF 0.70 (0.21) 0.81 (0.19) 0.08 (0.20) 0.63 (0.17) 0.57 (0.18) -0.04 (0.20) 0.1971 






(0.37) -0.11 (0.44) 0.3524 
Mean rMTT 6.02 (3.17) 3.77 (1.05) -1.18 (2.54) 5.68 (3.17) 4.08 (2.39) -2.65 (1.99) 0.1732 
* Two-sample t-test with equal variances.  
Abbreviations: rCBF, cerebral blood flow; rCBV, cerebral blood 
volume; rMTT, mean transit time; ROI, region of interest.




The aim of this thesis was to evaluate the neuroprotective effect of 
theophylline in patients with acute ischemic stroke. 
The TEA-Stroke trial protocol provided a study design involving the 
administration of theophylline as an adjunct to thrombolytic therapy 
that considered the important limitations of previous clinical trials 
(Study I). The trial was terminated early because of the low recruitment 
rate. No safety concerns were identified. The main outcome findings 
were: The co-primary endpoints clinical improvement and infarct 
volume growth at the 24-hour follow-up point were not significantly 
different between the theophylline group and the control group after 
correction for multiplicity (Study II). Voxel-by-voxel analysis of the 
multi-parametric MRI data, through the application of a machine 
learning model to predict the follow-up brain lesion volumes, revealed 
no significant difference in patients virtually treated with theophylline 
and placebo (Study III). Theophylline did not change the perfusion in 
the penumbra at the 3-hour follow-up, but affected the rCBV in the 
infarct core, with significantly higher values observed in the 
theophylline group (Study IV). 
The clinical and imaging outcomes of the main TEA-Stroke trial and 
the sub-studies are somewhat contradictory. 
Clinical endpoints 
Theophylline improved the NIHSS score between baseline and 24-hour 
follow-up by 4.7 points, compared with an improvement of 1.3 points 
in the control group (p=0.044). This was not statistically significant 
after correction for multiplicity with a significance level of α=0.025, as 
the clinical improvement was part of the co-primary endpoint (Study 
II). The trial was primarily designed to include patients with moderate 
to severe symptoms of acute ischemic stroke and an MRI indicative of 
a salvageable penumbra, as these patients might benefit most from a 
putative neuroprotective effect of theophylline. The subgroup analysis 
of patients with more severe stroke symptoms did support our 
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hypothesis that these patients benefit most, but the low sample size 
precluded the formation of a definitive conclusion. The low number of 
patients subsequently recruited, and the early termination of the trial 
was a result of patients with more severe stroke symptoms often unable 
to provide informed consent, a recognized rate-limiting step in acute 
clinical stroke trials.(94,95) 
The secondary endpoints of early clinical improvement from baseline 
to the 3-hour follow-up point and functional clinical outcome at 90 days 
(functional independence and categorical functional outcome on the 
mRS) were not significantly different between the two treatment groups 
but were not statistically powered to detect meaningful differences. The 
fact that there was no death or severe disability in the theophylline 
group compared to three patients in the control group might be due to 
chance.  
The trend towards clinical improvement, but without statistical 
significance, is in line with previous clinical trials with theophylline in 
stroke patients.(73,74) Although they share the problem of low sample 
sizes, the previous trials additionally suffered from inadequate patient 
selection, lack of revascularization therapy, and delayed intervention as 
presumed reasons for their failure to show statistically significant 
results.  
Imaging endpoints 
The co-primary imaging endpoint did not confirm reduced infarct 
volume growth at the 24-hour follow-up point in the theophylline group 
compared to the control group. Infarct volume growth was selected as 
a co-primary endpoint because infarct volume growth has been 
previously described as a surrogate marker for good long-term 
outcome.(25,83) However, two recent randomized clinical trials 
involving acute interventions in ischemic stroke demonstrated 
significant clinical improvements despite no significant reduction in 
infarct volume growth being observed. The MRI-Guided Thrombolysis 
for Stroke With Unknown Time of Onset (wake-up) trial in patients 
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with acute ischemic stroke of unknown onset treated with 
thrombolysis,(96) and the Thrombectomy for Stroke at 6 to 16 Hours 
with selection by perfusion imaging (DEFUSE III) trial,(13) both 
showed low number-needed-to-treat values in achieving functional 
independence of stroke patients at 90 days. Despite highly favorable 
clinical outcomes, no significant reduction in the growth of infarct 
volume was observed, indicating that infarct volume growth at 24-hour 
follow-up might be less suitable as an imaging surrogate endpoint.   
However, the infarct volume growth information in these trials, and in 
the main TEA-Stroke trial (Study II), was limited to follow-up T2-
FLAIR MRI segmentation. Thus, it was unclear whether the small 
sample size and the considerably large variation of stroke volumes in 
the TEA-Stroke trial might prevent the detection of a subtle 
neuroprotective effect of theophylline. The sub-study was designed 
with the voxel-by-voxel analysis of 8 multi-parametric MRI 
parameters, and 4 clinical parameters, to amplify the outcome 
information (Study III). Furthermore, the machine learning model 
approach to predict the follow-up brain lesion volumes essentially 
doubled the sample size. However, the predicted follow-up lesion 
volumes were almost identical in patients virtually treated with 
theophylline and placebo. This was also true for patients with penumbra 
and/or subsequent revascularization, a highly selected group of patients 
that would be most likely to benefit from neuroprotection. The lack of 
a neuroprotective effect of theophylline on infarct volume growth might 
be explained by the results of the last sub-study designed to evaluate 
the change in cerebral perfusion induced by theophylline (Study IV). 
This analysis showed that theophylline did not change cerebral 
perfusion in the salvageable penumbra and only affected the rCBV in 
the infarct core. It should be mentioned that even though CBF, CBV, 
and MTT were used in previous studies to define the penumbra and 
infarct core,(52,97,98) the precise thresholds to distinguish these two 
areas from each other, as well as the final outcome prediction, varies 
between studies.(99–101) The decreased signal in the ADC maps was 
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used to define the infarct core in this sub-study analysis. Dreier et al. 
depict spreading depolarization as the principal mechanism that 
mediates neuronal death in ischemic stroke.(102) This mechanism was 
described as a near-complete breakdown with cessation of spontaneous 
electrical activity, collapse of ion gradients, and consecutive cytotoxic 
edema. The cytotoxic edema is detectable as restricted diffusion with 
decreased signal in the ADC maps. However, normalization of the ADC 
signal may occur in acute stroke after tissue reperfusion, especially 
within 3 hours after stroke onset and brain tissue with initially decreased 
ADC signal may also include tissue at risk.(103) In the penumbra, a 
cluster of repetitive prolonged spreading depolarization is typical and 
initially reversible, whereas in the infarct core, it is often a single 
terminal event causing neuronal death.(102) This contributes to the 
uncertainty of the correct differentiation and the dynamic over time of 
the infarct core and penumbra that might limit the interpretation of the 
perfusion changes in this sub-study. Another issue is the presence of 
experimental evidence showing that adenosine released by astrocytes 
during ischemia might have a protective effect on neurons and the 
microcirculation(58,104) by activating adenosine triphosphate-
dependent membrane pumps required in the recovery from spreading 
depolarization.(102) Theophylline, however, acts as competitive 
adenosine receptor antagonist(56) and antagonization of adenosine in 
the infarct core and penumbra might be counterproductive in the 
concept of neuroprotection by theophylline.    
Regarding the sub-study results of this dissertation, it is uncertain 
whether the increased rCBV in the infarct core in the theophylline group 
was caused by the potentially positive chronotropic and inotropic 
effects of theophylline, but the significant difference in heart rate with 
higher values in the theophylline group might support this theory. The 
inverse intracerebral steal phenomenon or ‘Robin Hood effect’ of 
theophylline described in previous trials(59) might provide another 
explanation. However, the data from this sub-study do not support the 
theory of redistribution from healthy brain tissue to the stroke-affected 
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areas, as the perfusion in the unaffected brain tissue and the penumbra 
remained unchanged. If this was present at all, it was limited to the 
infarct core and unlikely to be salvageable. This might explain why 
theophylline did not show a more substantial clinical improvement 
(Study II) and did not reduce the infarct volume growth (Study III). 
The main strength of the TEA-Stroke trial and sub-studies was that they 
were based on a randomized, double-blind, placebo-controlled study 
design. The protocol was designed to select patients with MRI-verified 
ischemic stroke within the acute phase of 4.5 hours after symptom 
onset, with the presence of salvageable penumbra, and as an adjunct to 
thrombolytic therapy to offset the shortcomings of previous clinical 
trials (Study I). The trial randomization and treatment concealment 
were effective, and the outcome assessment was blinded and complete 
(Study II). The quality of all perfusion MRI datasets was sufficient for 
analysis (studies III and IV). However, the main limitation was the slow 
recruitment rate and the early termination of the trial despite three 
amendments. The inability of patients with moderate and severe stroke 
symptoms to provide informed consent was a major factor contributing 
to screening failure. Consent by proxy was not permitted by the Danish 
Health and Medicine Authorities when the study was designed back in 
2013. Furthermore, recruitment of new sites in Denmark and Europe 
was not possible, as the trial protocol and in particular the acute multi-
parametric MRI studies were challenging for other sites.





The aim of this thesis was met as it evaluated the neuroprotective effect 
of theophylline as an adjunct to thrombolytic therapy in patients with 
acute ischemic stroke. The TEA-Stroke trial was designed and 
performed to offset the shortcomings of previous clinical trials. No 
significant safety concerns were identified. The co-primary clinical 
endpoint alone could have shown early clinical improvement in the 
theophylline group but was not statistically significant after correction 
for multiplicity. The co-primary endpoint of infarct volume growth was 
similar in both treatment groups. A machine learning approach to 
predict the follow-up lesions for each patient virtually treated with 
theophylline and placebo was applied. This approach adjusted for the 
large variation of stroke volumes in a small sample size and confirmed 
that theophylline did not reduce the infarct volume growth. 
Furthermore, the analysis of cerebral perfusion showed that 
theophylline did not change the perfusion in the salvageable penumbra, 
but only affected the cerebral blood volume in the infarct core. In 
contrast to the penumbra, the infarct core is very unlikely to be 
salvageable, which might explain why theophylline failed to reduce the 
final infarct volume and failed to substantially improve the clinical 
outcome. 
 
Suggestions for Further Research 
The results of the TEA-Stroke trial should be added to the growing body 
of neuroprotective clinical trials that have failed to translate promising 
results from pre-clinical stroke models to humans.(105) However, the 
traditional scientific definition of neuroprotection refers to the 
minimization of the harmful effect of ischemia at the level of the neuron 
and, from the pragmatic point of view of patients and physicians, 
neuroprotection means maintaining neuronal damage under the 
threshold of symptom manifestation.(38) With this in mind, this proof-
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of-concept trial might encourage a further clinical trial designed to 
search for a clinically meaningful neuroprotective effect of 
theophylline. However, the clinical effect in the TEA-Stroke trial was 
small, and the potential neuroprotective effect could not be supported 
by the imaging data. Furthermore, it must be remembered that 
theophylline has potentially serious side effects, although this trial had 
no clinically relevant safety concerns. In summary, the data of this 
thesis are not strong enough to support further research on theophylline 
as a neuroprotective agent, as the balance between potential clinically 
meaningful benefit and harm of theophylline in acute ischemic stroke 
remains questionable.
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Appendix A (1/6): National Institute of Health Stroke Scale (NIHSS) 







Patient Identification. ___ ___-___ ___ ___-___ ___ ___ 
 
     Pt. Date of Birth ___ ___/___ ___/___ ___ 
 
Hospital ________________________(___ ___-___ ___) 
 
Date of Exam ___ ___/___ ___/___ ___ 
 
            
Interval: [ ] Baseline [ ] 2 hours post treatment    [ ] 24 hours post onset of symptoms ±20 minutes    [ ] 7-10 days          
 [ ] 3 months [ ] Other ________________________________(___ ___) 
 
Time: ___ ___:___ ___   [ ]am [ ]pm
Person Administering Scale _____________________________________  
Administer stroke scale items in the order listed.  Record performance in each category after each subscale exam.  Do not go 
back and change scores.  Follow directions provided for each exam technique.  Scores should reflect what the patient does, not 
what the clinician thinks the patient can do.  The clinician should record answers while administering the exam and work quickly. 
Except where indicated, the patient should not be coached (i.e., repeated requests to patient to make a special effort). 
Instructions   Scale Definition Score 
1a.  Level of Consciousness: The investigator must choose a 
response if a full evaluation is prevented by such obstacles as an 
endotracheal tube, language barrier, orotracheal trauma/bandages.  A 
3 is scored only if the patient makes no movement (other than reflexive 
posturing) in response to noxious stimulation. 
 0 =    Alert; keenly responsive. 
 1 = Not alert; but arousable by minor stimulation to obey, 
answer, or respond. 
 2 = Not alert; requires repeated stimulation to attend, or is 
obtunded and requires strong or painful stimulation to 
make movements (not stereotyped). 
 3 = Responds only with reflex motor or autonomic effects or 
totally unresponsive, flaccid, and areflexic. 
______ 
1b.  LOC Questions:  The patient is asked the month and his/her age. 
The answer must be correct - there is no partial credit for being close.  
Aphasic and stuporous patients who do not comprehend the questions 
will score 2.  Patients unable to speak because of endotracheal 
intubation, orotracheal trauma, severe dysarthria from any cause, 
language barrier, or any other problem not secondary to aphasia are 
given a 1.  It is important that only the initial answer be graded and that 
the examiner not "help" the patient with verbal or non-verbal cues. 
 0 = Answers both questions correctly. 
 1 = 
 
Answers one question correctly. 
 2 = Answers neither question correctly.  
______ 
1c.  LOC Commands:  The patient is asked to open and close the 
eyes and then to grip and release the non-paretic hand.  Substitute 
another one step command if the hands cannot be used.  Credit is 
given if an unequivocal attempt is made but not completed due to 
weakness.  If the patient does not respond to command, the task 
should be demonstrated to him or her (pantomime), and the result 
scored (i.e., follows none, one or two commands).  Patients with 
trauma, amputation, or other physical impediments should be given 
suitable one-step commands.  Only the first attempt is scored. 
 0 = Performs both tasks correctly. 
 1 = Performs one task correctly. 
 2 = Performs neither task correctly. ______ 
2.  Best Gaze:  Only horizontal eye movements will be tested.  
Voluntary or reflexive (oculocephalic) eye movements will be scored, 
but caloric testing is not done.  If the patient has a conjugate 
deviation of the eyes that can be overcome by voluntary or reflexive 
activity, the score will be 1.  If a patient has an isolated peripheral 
nerve paresis (CN III, IV or VI), score a 1.  Gaze is testable in all 
aphasic patients.  Patients with ocular trauma, bandages, pre-existing 
blindness, or other disorder of visual acuity or fields should be tested 
with reflexive movements, and a choice made by the investigator.  
Establishing eye contact and then moving about the patient from side 
to side will occasionally clarify the presence of a partial gaze palsy.  
 0 = Normal. 
 1 = Partial gaze palsy; gaze is abnormal in one or both eyes, 
but forced deviation or total gaze paresis is not present. 
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Appendix A (2/6): National Institute of Health Stroke Scale (NIHSS) 






Patient Identification. ___ ___-___ ___ ___-___ ___ ___ 
 
     Pt. Date of Birth ___ ___/___ ___/___ ___ 
 
Hospital ________________________(___ ___-___ ___) 
 
Date of Exam ___ ___/___ ___/___ ___ 
 
            
Interval: [ ] Baseline [ ] 2 hours post treatment    [ ] 24 hours post onset of symptoms ±20 minutes    [ ] 7-10 days          
 [ ] 3 months [ ] Other ________________________________(___ ___) 
 
3.  Visual:  Visual fields (upper and lower quadrants) are tested by 
confrontation, using finger counting or visual threat, as appropriate.  
Patients may be encouraged, but if they look at the side of the 
moving fingers appropriately, this can be scored as normal.  If there is 
unilateral blindness or enucleation, visual fields in the remaining eye 
are scored.  Score 1 only if a clear-cut asymmetry, including 
quadrantanopia, is found.  If patient is blind from any cause, score 3.  
Double simultaneous stimulation is performed at this point.  If there is 
extinction, patient receives a 1, and the results are used to respond to 
item 11. 
 0 = No visual loss. 
 1 = Partial hemianopia. 
 2 = Complete hemianopia. 
 3 = Bilateral hemianopia (blind including cortical blindness). 
______ 
4.  Facial Palsy:  Ask – or use pantomime to encourage – the patient 
to show teeth or raise eyebrows and close eyes.  Score symmetry of 
grimace in response to noxious stimuli in the poorly responsive or 
non-comprehending patient.  If facial trauma/bandages, orotracheal 
tube, tape or other physical barriers obscure the face, these should 
be removed to the extent possible. 
 0 = Normal symmetrical movements. 
 1 = Minor paralysis (flattened nasolabial fold, asymmetry on 
smiling). 
 2 = Partial paralysis (total or near-total paralysis of lower 
face). 
 3 = Complete paralysis of one or both sides (absence of 
facial movement in the upper and lower face). 
______ 
5.  Motor Arm:  The limb is placed in the appropriate position: extend 
the arms (palms down) 90 degrees (if sitting) or 45 degrees (if 
supine).  Drift is scored if the arm falls before 10 seconds.  The 
aphasic patient is encouraged using urgency in the voice and 
pantomime, but not noxious stimulation.  Each limb is tested in turn, 
beginning with the non-paretic arm.  Only in the case of amputation or 
joint fusion at the shoulder, the examiner should record the score as 
untestable (UN), and clearly write the explanation for this choice. 
  0 =  No drift; limb holds 90 (or 45) degrees for full 10 seconds. 
  1 =  Drift; limb holds 90 (or 45) degrees, but drifts down before 
full 10 seconds; does not hit bed or other support. 
  2 =  Some effort against gravity; limb cannot get to or 
maintain (if cued) 90 (or 45) degrees, drifts down to bed, 
but has some effort against gravity. 
  3 =  No effort against gravity; limb falls. 
  4 =  No movement. 
  UN = Amputation or joint fusion, explain:  _____________________ 
 5a.  Left Arm  
 5b.  Right Arm  
______ 
______ 
6.  Motor Leg:  The limb is placed in the appropriate position:  hold 
the leg at 30 degrees (always tested supine).  Drift is scored if the leg 
falls before 5 seconds.  The aphasic patient is encouraged using 
urgency in the voice and pantomime, but not noxious stimulation.  
Each limb is tested in turn, beginning with the non-paretic leg.  Only 
in the case of amputation or joint fusion at the hip, the examiner 
should record the score as untestable (UN), and clearly write the 
explanation for this choice. 
  0 =  No drift; leg holds 30-degree position for full 5 seconds. 
  1 =  Drift; leg falls by the end of the 5-second period but does 
not hit bed.    
  2 =  Some effort against gravity; leg falls to bed by 5 
seconds, but has some effort against gravity. 
  3 =  No effort against gravity; leg falls to bed immediately. 
  4 =  No movement. 
  UN = Amputation or joint fusion, explain: ________________ 
6a.  Left Leg 
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Patient Identification. ___ ___-___ ___ ___-___ ___ ___ 
 
     Pt. Date of Birth ___ ___/___ ___/___ ___ 
 
Hospital ________________________(___ ___-___ ___) 
 
Date of Exam ___ ___/___ ___/___ ___ 
 
            
Interval: [ ] Baseline [ ] 2 hours post treatment    [ ] 24 hours post onset of symptoms ±20 minutes    [ ] 7-10 days          
 [ ] 3 months [ ] Other ________________________________(___ ___) 
 
______ 
7.  Limb Ataxia:  This item is aimed at finding evidence of a unilateral 
cerebellar lesion.  Test with eyes open.  In case of visual defect, 
ensure testing is done in intact visual field.  The finger-nose-finger 
and heel-shin tests are performed on both sides, and ataxia is scored 
only if present out of proportion to weakness.  Ataxia is absent in the 
patient who cannot understand or is paralyzed.  Only in the case of 
amputation or joint fusion, the examiner should record the score as 
untestable (UN), and clearly write the explanation for this choice.  In 
case of blindness, test by having the patient touch nose from 
extended arm position. 
 0 = Absent. 
 1 = Present in one limb. 
 2 = Present in two limbs. 
 UN = Amputation or joint fusion, explain:  ________________ 
______ 
8.  Sensory:  Sensation or grimace to pinprick when tested, or 
withdrawal from noxious stimulus in the obtunded or aphasic patient.  
Only sensory loss attributed to stroke is scored as abnormal and the 
examiner should test as many body areas (arms [not hands], legs, 
trunk, face) as needed to accurately check for hemisensory loss.  A 
score of 2, “severe or total sensory loss,” should only be given when 
a severe or total loss of sensation can be clearly demonstrated.  
Stuporous and aphasic patients will, therefore, probably score 1 or 0. 
The patient with brainstem stroke who has bilateral loss of sensation 
is scored 2.  If the patient does not respond and is quadriplegic, score 
2.  Patients in a coma (item 1a=3) are automatically given a 2 on this 
item. 
 0 = Normal; no sensory loss. 
 1 = Mild-to-moderate sensory loss; patient feels pinprick is 
less sharp or is dull on the affected side; or there is a 
loss of superficial pain with pinprick, but patient is aware 
of being touched. 
 2 = Severe to total sensory loss; patient is not aware of 
being touched in the face, arm, and leg. 
______ 
9.  Best Language:  A great deal of information about comprehension 
will be obtained during the preceding sections of the examination.  
For this scale item, the patient is asked to describe what is happening 
in the attached picture, to name the items on the attached naming 
sheet and to read from the attached list of sentences.  
Comprehension is judged from responses here, as well as to all of 
the commands in the preceding general neurological exam.  If visual 
loss interferes with the tests, ask the patient to identify objects placed 
in the hand, repeat, and produce speech.  The intubated patient 
should be asked to write. The patient in a coma (item 1a=3) will 
automatically score 3 on this item.  The examiner must choose a 
score for the patient with stupor or limited cooperation, but a score of 
3 should be used only if the patient is mute and follows no one-step 
commands. 
 0 = No aphasia; normal. 
 1 =  Mild-to-moderate aphasia; some obvious loss of fluency 
or facility of comprehension, without significant 
limitation on ideas expressed or form of expression.  
Reduction of speech and/or comprehension, however, 
makes conversation about provided materials difficult 
or impossible.  For example, in conversation about 
provided materials, examiner can identify picture or 
naming card content from patient’s response. 
 2 = Severe aphasia; all communication is through fragmentary 
expression; great need for inference, questioning, and guessing 
by the listener.  Range of information that can be exchanged is 
limited; listener carries burden of communication.  Examiner 
cannot identify materials provided from patient response. 
 3 = Mute, global aphasia; no usable speech or auditory 
comprehension. 
______ 
10.  Dysarthria: If patient is thought to be normal, an adequate 
sample of speech must be obtained by asking patient to read or 
repeat words from the attached list.  If the patient has severe 
aphasia, the clarity of articulation of spontaneous speech can be 
rated.  Only if the patient is intubated or has other physical barriers to 
producing speech, the examiner should record the score as 
untestable (UN), and clearly write an explanation for this choice.  Do 
not tell the patient why he or she is being tested. 
 0 = Normal. 
 1 = Mild-to-moderate dysarthria; patient slurs at least some 
words and, at worst, can be understood with some 
difficulty. 
 2 = Severe dysarthria; patient's speech is so slurred as to be 
unintelligible in the absence of or out of proportion to 
any dysphasia, or is mute/anarthric. 
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Appendix A (4/6): National Institute of Health Stroke Scale (NIHSS) 







Patient Identification. ___ ___-___ ___ ___-___ ___ ___ 
 
     Pt. Date of Birth ___ ___/___ ___/___ ___ 
 
Hospital ________________________(___ ___-___ ___) 
 
Date of Exam ___ ___/___ ___/___ ___ 
 
            
Interval: [ ] Baseline [ ] 2 hours post treatment    [ ] 24 hours post onset of symptoms ±20 minutes    [ ] 7-10 days          
 [ ] 3 months [ ] Other ________________________________(___ ___) 
 
11.  Extinction and Inattention (formerly Neglect):  Sufficient 
information to identify neglect may be obtained during the prior 
testing.  If the patient has a severe visual loss preventing visual 
double simultaneous stimulation, and the cutaneous stimuli are 
normal, the score is normal.  If the patient has aphasia but does 
appear to attend to both sides, the score is normal.  The presence of 
visual spatial neglect or anosagnosia may also be taken as evidence 
of abnormality.  Since the abnormality is scored only if present, the 
item is never untestable.   
 0 = No abnormality. 
 1 = Visual, tactile, auditory, spatial, or personal inattention 
or extinction to bilateral simultaneous stimulation in one 
of the sensory modalities. 
 2 = Profound hemi-inattention or extinction to more than 
one modality; does not recognize own hand or orients 
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You know how. 
Down to earth. 
I got home from work. 
Near the table in the dining 
room. 
They heard him speak on the 
radio last night. 
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TIP – TOP 
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Appendix B: Modified Rankin Scale (mRS)  
(Provided by the Internet Stroke Center — www.strokecenter.org) 
 
Provided by the Internet Stroke Center — www.strokecenter.org 
MODIFIED Patient Name: ___________________________  
RANKIN Rater Name: ___________________________  




0 No symptoms at all 
 
 
1 No significant disability despite symptoms; able to carry out all usual duties and activities 
 
 




3 Moderate disability; requiring some help, but able to walk without assistance 
 
 
4 Moderately severe disability; unable to walk without assistance and unable to attend to own bodily 
needs without assistance 
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